The Olivia-Newton John Cancer Research Institute (ONJCRI) is thrilled to welcome Dr Benjamin Gully and the Immunosurveillance Laboratory to our vibrant community of world-class scientists. Dr Gully's innovative research on immune regulation and his passion for translational science align perfectly with ONJCRI's mission to turn groundbreaking discoveries into life-changing treatments.
Bridging Discovery and Patient Impact
For Dr Gully, joining ONJCRI offers an opportunity to take his lab’s foundational research closer to the clinic — and closer to the people who need it most.
“ONJCRI provides an exceptional platform for translating fundamental research into real-world impact,” Dr Gully said. “The Institute’s clear focus on improving cancer outcomes aligns perfectly with the direction we want to take in our research, and we’re excited to be part of this community.”
Uncovering the Secrets of Immune Cells
At the heart of the Immunosurveillance Laboratory’s work is the mission to understand how immune cells interact with cancer — and how those interactions can be harnessed to destroy cancer cells. The lab has already made significant discoveries about the molecular pathways that regulate T cells, NK cells, and particularly γδ T cells, shedding light on their crucial roles in maintaining immune balance.
Bringing deep expertise in advanced microscopy and structural biology, the lab offers a unique ability to study immune cell behaviour at an unprecedented level of detail. Now, at ONJCRI, Dr Gully’s team will apply this knowledge to explore how these cells respond to cancer and how their natural abilities can be enhanced to create more effective therapies.
“Our goal is to understand immune cell regulation in cancer at its most intricate levels and use that knowledge to develop smarter, more targeted treatments,” Dr Gully explained.
One of the team’s most exciting areas of research focuses on γδ T cells — a remarkable subset of immune cells with powerful, natural tumour-targeting properties. By harnessing these unique capabilities, Dr Gully’s team aims to develop novel immunotherapies that are not only highly effective but also more precise and less toxic for patients.
“γδ T cells hold incredible potential for reshaping cancer care,” Dr Gully said. “At ONJCRI, we’re eager to advance this work and bring new treatment strategies closer to reality.”
A Personal Commitment to Cancer Research
Dr Gully’s dedication to cancer research is driven by a strong belief in the power of science to drive positive change. His passion for improving patient outcomes has guided his transition from basic research to more applied, translational work.
“I care deeply about the role that academic and translational research play in advancing patient care,” he said. “Throughout my career, I have aimed to progress into research that can directly help those facing cancer and other unmet health challenges.”
Inspiring the Next Generation of Researchers
Beyond his pioneering research, Dr Gully is deeply committed to mentoring young scientists, encouraging them to embrace curiosity, dedication, and innovation.
“Find a field that truly inspires you and stay committed to it,” he advised. “Research can sometimes feel isolating, but when you pursue work you’re passionate about and stay open to new technologies and ideas, you’ll build a rewarding and impactful career.”
Looking to the Future
As Dr Gully and the Immunosurveillance Laboratory join ONJCRI, we look forward to the collaborations, discoveries, and innovations they will bring. Their expertise and vision will help drive the development of next-generation cancer immunotherapies — offering new hope to patients and pushing the boundaries of what’s possible in cancer care.
Stay connected as Dr Gully’s team continues their groundbreaking work, transforming immune system insights into therapies that will shape the future of cancer treatment.